EGFR and neoplasm: The Response Evaluation Criteria for Solid Tumours (RECIST 1.1) provides an objective, standardized method for assessing the efficacy of EGFR-TKIs (Eisenhauer et al., 2009), and requires the visual assessment of the tumor size based on radiological imaging (Mayerhoefer et al., 2020).